Biotech’s Cathedral Problem: Why Emerging Companies Must Rethink Lab Infrastructure
Buildings from Boston’s recent biotech boom were designed for a different kind of market. That’s why it’s been so hard to fill them. But there’s another way.
Greater Boston’s Lab Market Is Improving, But Most Tenants Still Play It Safe
While improving, demand-side fundamentals in Greater Boston’s laboratory market remain challenged as life science users continue to exhibit cautiousness in their real estate decisions.
MassBio Maps Rescue Plan for Life Science Startups
The free-flowing funding climate in biotech slowed to a trickle in 2022, choking off the supply of tenants to fill Boston’s explosion of new life science real estate.
Is Something Frightening Hiding in REIT’s Retrenchment?
Moves by the California-based Alexandria Real Estate Equities to dump a significant slice of its Boston-area life science real estate portfolio speak volumes about the state of the local lab market, none of it good.
